0 Ratings

ID

4342

Description

ODM derived from http://clinicaltrials.gov/show/NCT01021670

Link

http://clinicaltrials.gov/show/NCT01021670

Keywords

  1. 12/7/13 12/7/13 - Martin Dugas
Uploaded on

December 7, 2013

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :


    No comments

    In order to download data models you must be logged in. Please log in or register for free.

    Eligibility NCT01021670 Sexual Dysfunction, Physiological

    Eligibility

    1. StudyEvent: Eligibility
      1. Eligibility
    Inclusion Criteria
    Description

    Inclusion Criteria

    Alias
    UMLS CUI 2011AA
    CL425202
    age 18 Years to 64 Years
    Description

    age 18 Years to 64 Years

    Data type

    boolean

    Alias
    UMLS CUI 2011AA
    C0001779
    SNOMED CT 2011_0131
    397669002
    In accordance with the therapeutic indication stated in the Summary of Product Characteristics for dapoxetine hydrochloride, patients will be candidates for enrollment if they have an intravaginal ejaculatory latency time of < two minutes
    Description

    In accordance with the therapeutic indication stated in the Summary of Product Characteristics for dapoxetine hydrochloride, patients will be candidates for enrollment if they have an intravaginal ejaculatory latency time of < two minutes

    Data type

    boolean

    Alias
    UMLS CUI 2011AA
    C0332290
    SNOMED CT 2011_0131
    385433004
    UMLS CUI 2011AA
    C1709515
    UMLS CUI 2011AA
    C0039798
    UMLS CUI 2011AA
    CL335836
    UMLS CUI 2011AA
    C0970823
    UMLS CUI 2011AA
    C0442122
    SNOMED CT 2011_0131
    264049007
    UMLS CUI 2011AA
    C0013746
    SNOMED CT 2011_0131
    40335009
    UMLS CUI 2011AA
    C0205275
    SNOMED CT 2011_0131
    44104002
    UMLS CUI 2011AA
    C0040223
    SNOMED CT 2011_0131
    410670007
    LOINC Version 232
    MTHU009151
    Persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration and before the patient wishes
    Description

    Persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration and before the patient wishes

    Data type

    boolean

    Alias
    UMLS CUI 2011AA
    C0205322
    UMLS CUI 2011AA
    C2945760
    SNOMED CT 2011_0131
    255227004
    UMLS CUI 2011AA
    C0013746
    SNOMED CT 2011_0131
    40335009
    UMLS CUI 2011AA
    C0547040
    SNOMED CT 2011_0131
    255605001
    UMLS CUI 2011AA
    C0036864
    SNOMED CT 2011_0131
    363903009
    UMLS CUI 2011AA
    C1292856
    SNOMED CT 2011_0131
    122545008
    Marked personal distress or interpersonal difficulty as a consequence of premature ejaculation
    Description

    Marked personal distress or interpersonal difficulty as a consequence of premature ejaculation

    Data type

    boolean

    Alias
    UMLS CUI 2011AA
    C1706089
    UMLS CUI 2011AA
    C0681884
    UMLS CUI 2011AA
    C0231303
    SNOMED CT 2011_0131
    69328002
    MedDRA 14.1
    10013487
    UMLS CUI 2011AA
    C0814588
    UMLS CUI 2011AA
    CL420107
    UMLS CUI 2011AA
    C0033038
    SNOMED CT 2011_0131
    44001008
    MedDRA 14.1
    10036596
    ICD-10-CM Version 2010
    F52.4
    ICD-9-CM Version 2011
    302.75
    UMLS CUI 2011AA
    C0011900
    SNOMED CT 2011_0131
    439401001
    LOINC Version 232
    MTHU008876
    Poor control over ejaculation
    Description

    Poor control over ejaculation

    Data type

    boolean

    Alias
    UMLS CUI 2011AA
    C2700379
    UMLS CUI 2011AA
    C2587213
    SNOMED CT 2011_0131
    31509003
    UMLS CUI 2011AA
    C0013746
    SNOMED CT 2011_0131
    40335009
    Exclusion Criteria
    Description

    Exclusion Criteria

    Alias
    UMLS CUI 2011AA
    CL425201
    In accordance with the contraindications, special warnings and precautions for use as stated in the Summary of Product Characteristics for dapoxetine hydrochloride, patients will be excluded from treatment if they have hypersensitivity to dapoxetine hydrochloride or to any of the excipients
    Description

    In accordance with the contraindications, special warnings and precautions for use as stated in the Summary of Product Characteristics for dapoxetine hydrochloride, patients will be excluded from treatment if they have hypersensitivity to dapoxetine hydrochloride or to any of the excipients

    Data type

    boolean

    Alias
    UMLS CUI 2011AA
    C0332290
    SNOMED CT 2011_0131
    385433004
    UMLS CUI 2011AA
    C1301624
    SNOMED CT 2011_0131
    397745006
    UMLS CUI 2011AA
    C1709515
    UMLS CUI 2011AA
    C0020517
    SNOMED CT 2011_0131
    418634005
    ICD-10-CM Version 2010
    T78.40
    UMLS CUI 2011AA
    C0970823
    UMLS CUI 2011AA
    C0015237
    SNOMED CT 2011_0131
    360215002
    Significant pathological cardiac conditions such as: heart failure (New York Heart Association [NYHA] class II-IV), conduction abnormalities (second or third degree atrioventicular (AV) block or sick sinus syndrome) not treated with a permanent pacemaker, significant ischemic heart disease, or significant valvular disease
    Description

    Significant pathological cardiac conditions such as: heart failure (New York Heart Association [NYHA] class II-IV), conduction abnormalities (second or third degree atrioventicular (AV) block or sick sinus syndrome) not treated with a permanent pacemaker, significant ischemic heart disease, or significant valvular disease

    Data type

    boolean

    Alias
    UMLS CUI 2011AA
    C1522601
    UMLS CUI 2011AA
    C0348080
    SNOMED CT 2011_0131
    260905004
    HL7 V3 2006_05
    COND
    UMLS CUI 2011AA
    C0018801
    SNOMED CT 2011_0131
    155374007
    MedDRA 14.1
    10019279
    ICD-9-CM Version 2011
    428
    CTCAE 1105E
    E10124
    UMLS CUI 2011AA
    C1319794
    SNOMED CT 2011_0131
    421704003
    MedDRA 14.1
    10064080
    UMLS CUI 2011AA
    C1319795
    SNOMED CT 2011_0131
    420913000
    MedDRA 14.1
    10064081
    UMLS CUI 2011AA
    C1319796
    SNOMED CT 2011_0131
    422293003
    MedDRA 14.1
    10064082
    UMLS CUI 2011AA
    C1842820
    UMLS CUI 2011AA
    C0264906
    SNOMED CT 2011_0131
    195042002
    MedDRA 14.1
    10003677
    ICD-10-CM Version 2010
    I44.1
    UMLS CUI 2011AA
    C0151517
    SNOMED CT 2011_0131
    27885002
    MedDRA 14.1
    10003673
    ICD-10-CM Version 2010
    I44.2
    ICD-9-CM Version 2011
    426.0
    CTCAE 1105E
    E10093
    UMLS CUI 2011AA
    C0037052
    SNOMED CT 2011_0131
    36083008
    MedDRA 14.1
    10040639
    ICD-10-CM Version 2010
    I49.5
    CTCAE 1105E
    E10202
    UMLS CUI 2011AA
    C0151744
    SNOMED CT 2011_0131
    414795007, 414545008
    MedDRA 14.1
    10028600
    LOINC Version 232
    MTHU024507
    ICD-10-CM Version 2010
    I20-I25
    ICD-9-CM Version 2011
    410-414.99
    UMLS CUI 2011AA
    C0026265
    SNOMED CT 2011_0131
    11851006
    MedDRA 14.1
    10061532
    ICD-9-CM Version 2011
    424.0
    CTCAE 1105E
    E10134
    Concomitant treatment with monoamine oxidase inhibitors (MAOIs), or within 14 days of discontinuing treatment with an MAOI
    Description

    Concomitant treatment with monoamine oxidase inhibitors (MAOIs), or within 14 days of discontinuing treatment with an MAOI

    Data type

    boolean

    Alias
    UMLS CUI 2011AA
    C1707479
    UMLS CUI 2011AA
    C1444662
    SNOMED CT 2011_0131
    410546004
    UMLS CUI 2011AA
    C0039798
    UMLS CUI 2011AA
    C0026457
    Concomitant treatment with thioridazine, concomitant treatment with serotonin reuptake inhibitors (selective serotonin reuptake inhibitors [SSRIs], serotonin-norepinephrine reuptake inhibitors [SNRIs], tricyclic antidepressants [TCAs)] or other medicinal/herbal products with serotonergic effects (for example, L-tryptophan, triptans, tramadol, linezolid, lithium, St. John's Wort (Hypericum perforatum)
    Description

    Concomitant treatment with thioridazine, concomitant treatment with serotonin reuptake inhibitors (selective serotonin reuptake inhibitors [SSRIs], serotonin-norepinephrine reuptake inhibitors [SNRIs], tricyclic antidepressants [TCAs)] or other medicinal/herbal products with serotonergic effects (for example, L-tryptophan, triptans, tramadol, linezolid, lithium, St. John's Wort (Hypericum perforatum)

    Data type

    boolean

    Alias
    UMLS CUI 2011AA
    C1707479
    UMLS CUI 2011AA
    C0039943
    SNOMED CT 2011_0131
    33588000
    LOINC Version 232
    MTHU003228
    UMLS CUI 2011AA
    C2911696
    UMLS CUI 2011AA
    C0360105
    SNOMED CT 2011_0131
    349854005
    UMLS CUI 2011AA
    C1579361
    UMLS CUI 2011AA
    C0003290
    SNOMED CT 2011_0131
    373253007
    LOINC Version 232
    MTHU001920
    UMLS CUI 2011AA
    C0041249
    SNOMED CT 2011_0131
    108952000
    LOINC Version 232
    MTHU004124
    UMLS CUI 2011AA
    C1567966
    UMLS CUI 2011AA
    C0040610
    SNOMED CT 2011_0131
    108507005
    LOINC Version 232
    MTHU003394
    UMLS CUI 2011AA
    C0663241
    SNOMED CT 2011_0131
    125695009
    LOINC Version 232
    MTHU013614
    UMLS CUI 2011AA
    C0023870
    SNOMED CT 2011_0131
    85899009
    LOINC Version 232
    MTHU004197
    UMLS CUI 2011AA
    C0936242
    SNOMED CT 2011_0131
    51621002
    Concomitant treatment of potent CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, saquinavir, telithromycin, nefazadone, nelfinavir, atazanavir, etc.
    Description

    Concomitant treatment of potent CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, saquinavir, telithromycin, nefazadone, nelfinavir, atazanavir, etc.

    Data type

    boolean

    Alias
    UMLS CUI 2011AA
    C1707479
    UMLS CUI 2011AA
    C1142644
    SNOMED CT 2011_0131
    422741004
    UMLS CUI 2011AA
    C0243077
    UMLS CUI 2011AA
    C0022625
    SNOMED CT 2011_0131
    387216007
    LOINC Version 232
    MTHU002299
    UMLS CUI 2011AA
    C0064113
    SNOMED CT 2011_0131
    387532006
    LOINC Version 232
    MTHU002298
    UMLS CUI 2011AA
    C0292818
    SNOMED CT 2011_0131
    386896009
    LOINC Version 232
    MTHU013855
    UMLS CUI 2011AA
    C0286738
    SNOMED CT 2011_0131
    108700005
    LOINC Version 232
    MTHU008513
    UMLS CUI 2011AA
    C1452484
    SNOMED CT 2011_0131
    395260006
    LOINC Version 232
    MTHU016681
    UMLS CUI 2011AA
    C0068485
    SNOMED CT 2011_0131
    108435006
    LOINC Version 232
    MTHU003461
    UMLS CUI 2011AA
    C0525005
    SNOMED CT 2011_0131
    108706004
    LOINC Version 232
    MTHU013848
    UMLS CUI 2011AA
    C1145759
    SNOMED CT 2011_0131
    413591007
    LOINC Version 232
    MTHU018644
    Moderate and severe hepatic impairment
    Description

    Moderate and severe hepatic impairment

    Data type

    boolean

    Alias
    UMLS CUI 2011AA
    C1881878
    UMLS CUI 2011AA
    C0205082
    SNOMED CT 2011_0131
    24484000
    UMLS CUI 2011AA
    C0948807
    MedDRA 14.1
    10052254

    Similar models

    Eligibility

    1. StudyEvent: Eligibility
      1. Eligibility
    Name
    Type
    Description | Question | Decode (Coded Value)
    Data type
    Alias
    Item Group
    Inclusion Criteria
    CL425202 (UMLS CUI 2011AA)
    age 18 Years to 64 Years
    Item
    age 18 Years to 64 Years
    boolean
    C0001779 (UMLS CUI 2011AA)
    397669002 (SNOMED CT 2011_0131)
    In accordance with the therapeutic indication stated in the Summary of Product Characteristics for dapoxetine hydrochloride, patients will be candidates for enrollment if they have an intravaginal ejaculatory latency time of < two minutes
    Item
    In accordance with the therapeutic indication stated in the Summary of Product Characteristics for dapoxetine hydrochloride, patients will be candidates for enrollment if they have an intravaginal ejaculatory latency time of < two minutes
    boolean
    C0332290 (UMLS CUI 2011AA)
    385433004 (SNOMED CT 2011_0131)
    C1709515 (UMLS CUI 2011AA)
    C0039798 (UMLS CUI 2011AA)
    CL335836 (UMLS CUI 2011AA)
    C0970823 (UMLS CUI 2011AA)
    C0442122 (UMLS CUI 2011AA)
    264049007 (SNOMED CT 2011_0131)
    C0013746 (UMLS CUI 2011AA)
    40335009 (SNOMED CT 2011_0131)
    C0205275 (UMLS CUI 2011AA)
    44104002 (SNOMED CT 2011_0131)
    C0040223 (UMLS CUI 2011AA)
    410670007 (SNOMED CT 2011_0131)
    MTHU009151 (LOINC Version 232)
    Persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration and before the patient wishes
    Item
    Persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration and before the patient wishes
    boolean
    C0205322 (UMLS CUI 2011AA)
    C2945760 (UMLS CUI 2011AA)
    255227004 (SNOMED CT 2011_0131)
    C0013746 (UMLS CUI 2011AA)
    40335009 (SNOMED CT 2011_0131)
    C0547040 (UMLS CUI 2011AA)
    255605001 (SNOMED CT 2011_0131)
    C0036864 (UMLS CUI 2011AA)
    363903009 (SNOMED CT 2011_0131)
    C1292856 (UMLS CUI 2011AA)
    122545008 (SNOMED CT 2011_0131)
    Marked personal distress or interpersonal difficulty as a consequence of premature ejaculation
    Item
    Marked personal distress or interpersonal difficulty as a consequence of premature ejaculation
    boolean
    C1706089 (UMLS CUI 2011AA)
    C0681884 (UMLS CUI 2011AA)
    C0231303 (UMLS CUI 2011AA)
    69328002 (SNOMED CT 2011_0131)
    10013487 (MedDRA 14.1)
    C0814588 (UMLS CUI 2011AA)
    CL420107 (UMLS CUI 2011AA)
    C0033038 (UMLS CUI 2011AA)
    44001008 (SNOMED CT 2011_0131)
    10036596 (MedDRA 14.1)
    F52.4 (ICD-10-CM Version 2010)
    302.75 (ICD-9-CM Version 2011)
    C0011900 (UMLS CUI 2011AA)
    439401001 (SNOMED CT 2011_0131)
    MTHU008876 (LOINC Version 232)
    Poor control over ejaculation
    Item
    Poor control over ejaculation
    boolean
    C2700379 (UMLS CUI 2011AA)
    C2587213 (UMLS CUI 2011AA)
    31509003 (SNOMED CT 2011_0131)
    C0013746 (UMLS CUI 2011AA)
    40335009 (SNOMED CT 2011_0131)
    Item Group
    Exclusion Criteria
    CL425201 (UMLS CUI 2011AA)
    In accordance with the contraindications, special warnings and precautions for use as stated in the Summary of Product Characteristics for dapoxetine hydrochloride, patients will be excluded from treatment if they have hypersensitivity to dapoxetine hydrochloride or to any of the excipients
    Item
    In accordance with the contraindications, special warnings and precautions for use as stated in the Summary of Product Characteristics for dapoxetine hydrochloride, patients will be excluded from treatment if they have hypersensitivity to dapoxetine hydrochloride or to any of the excipients
    boolean
    C0332290 (UMLS CUI 2011AA)
    385433004 (SNOMED CT 2011_0131)
    C1301624 (UMLS CUI 2011AA)
    397745006 (SNOMED CT 2011_0131)
    C1709515 (UMLS CUI 2011AA)
    C0020517 (UMLS CUI 2011AA)
    418634005 (SNOMED CT 2011_0131)
    T78.40 (ICD-10-CM Version 2010)
    C0970823 (UMLS CUI 2011AA)
    C0015237 (UMLS CUI 2011AA)
    360215002 (SNOMED CT 2011_0131)
    Significant pathological cardiac conditions such as: heart failure (New York Heart Association [NYHA] class II-IV), conduction abnormalities (second or third degree atrioventicular (AV) block or sick sinus syndrome) not treated with a permanent pacemaker, significant ischemic heart disease, or significant valvular disease
    Item
    Significant pathological cardiac conditions such as: heart failure (New York Heart Association [NYHA] class II-IV), conduction abnormalities (second or third degree atrioventicular (AV) block or sick sinus syndrome) not treated with a permanent pacemaker, significant ischemic heart disease, or significant valvular disease
    boolean
    C1522601 (UMLS CUI 2011AA)
    C0348080 (UMLS CUI 2011AA)
    260905004 (SNOMED CT 2011_0131)
    COND (HL7 V3 2006_05)
    C0018801 (UMLS CUI 2011AA)
    155374007 (SNOMED CT 2011_0131)
    10019279 (MedDRA 14.1)
    428 (ICD-9-CM Version 2011)
    E10124 (CTCAE 1105E)
    C1319794 (UMLS CUI 2011AA)
    421704003 (SNOMED CT 2011_0131)
    10064080 (MedDRA 14.1)
    C1319795 (UMLS CUI 2011AA)
    420913000 (SNOMED CT 2011_0131)
    10064081 (MedDRA 14.1)
    C1319796 (UMLS CUI 2011AA)
    422293003 (SNOMED CT 2011_0131)
    10064082 (MedDRA 14.1)
    C1842820 (UMLS CUI 2011AA)
    C0264906 (UMLS CUI 2011AA)
    195042002 (SNOMED CT 2011_0131)
    10003677 (MedDRA 14.1)
    I44.1 (ICD-10-CM Version 2010)
    C0151517 (UMLS CUI 2011AA)
    27885002 (SNOMED CT 2011_0131)
    10003673 (MedDRA 14.1)
    I44.2 (ICD-10-CM Version 2010)
    426.0 (ICD-9-CM Version 2011)
    E10093 (CTCAE 1105E)
    C0037052 (UMLS CUI 2011AA)
    36083008 (SNOMED CT 2011_0131)
    10040639 (MedDRA 14.1)
    I49.5 (ICD-10-CM Version 2010)
    E10202 (CTCAE 1105E)
    C0151744 (UMLS CUI 2011AA)
    414795007, 414545008 (SNOMED CT 2011_0131)
    10028600 (MedDRA 14.1)
    MTHU024507 (LOINC Version 232)
    I20-I25 (ICD-10-CM Version 2010)
    410-414.99 (ICD-9-CM Version 2011)
    C0026265 (UMLS CUI 2011AA)
    11851006 (SNOMED CT 2011_0131)
    10061532 (MedDRA 14.1)
    424.0 (ICD-9-CM Version 2011)
    E10134 (CTCAE 1105E)
    Concomitant treatment with monoamine oxidase inhibitors (MAOIs), or within 14 days of discontinuing treatment with an MAOI
    Item
    Concomitant treatment with monoamine oxidase inhibitors (MAOIs), or within 14 days of discontinuing treatment with an MAOI
    boolean
    C1707479 (UMLS CUI 2011AA)
    C1444662 (UMLS CUI 2011AA)
    410546004 (SNOMED CT 2011_0131)
    C0039798 (UMLS CUI 2011AA)
    C0026457 (UMLS CUI 2011AA)
    Concomitant treatment with thioridazine, concomitant treatment with serotonin reuptake inhibitors (selective serotonin reuptake inhibitors [SSRIs], serotonin-norepinephrine reuptake inhibitors [SNRIs], tricyclic antidepressants [TCAs)] or other medicinal/herbal products with serotonergic effects (for example, L-tryptophan, triptans, tramadol, linezolid, lithium, St. John's Wort (Hypericum perforatum)
    Item
    Concomitant treatment with thioridazine, concomitant treatment with serotonin reuptake inhibitors (selective serotonin reuptake inhibitors [SSRIs], serotonin-norepinephrine reuptake inhibitors [SNRIs], tricyclic antidepressants [TCAs)] or other medicinal/herbal products with serotonergic effects (for example, L-tryptophan, triptans, tramadol, linezolid, lithium, St. John's Wort (Hypericum perforatum)
    boolean
    C1707479 (UMLS CUI 2011AA)
    C0039943 (UMLS CUI 2011AA)
    33588000 (SNOMED CT 2011_0131)
    MTHU003228 (LOINC Version 232)
    C2911696 (UMLS CUI 2011AA)
    C0360105 (UMLS CUI 2011AA)
    349854005 (SNOMED CT 2011_0131)
    C1579361 (UMLS CUI 2011AA)
    C0003290 (UMLS CUI 2011AA)
    373253007 (SNOMED CT 2011_0131)
    MTHU001920 (LOINC Version 232)
    C0041249 (UMLS CUI 2011AA)
    108952000 (SNOMED CT 2011_0131)
    MTHU004124 (LOINC Version 232)
    C1567966 (UMLS CUI 2011AA)
    C0040610 (UMLS CUI 2011AA)
    108507005 (SNOMED CT 2011_0131)
    MTHU003394 (LOINC Version 232)
    C0663241 (UMLS CUI 2011AA)
    125695009 (SNOMED CT 2011_0131)
    MTHU013614 (LOINC Version 232)
    C0023870 (UMLS CUI 2011AA)
    85899009 (SNOMED CT 2011_0131)
    MTHU004197 (LOINC Version 232)
    C0936242 (UMLS CUI 2011AA)
    51621002 (SNOMED CT 2011_0131)
    Concomitant treatment of potent CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, saquinavir, telithromycin, nefazadone, nelfinavir, atazanavir, etc.
    Item
    Concomitant treatment of potent CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, saquinavir, telithromycin, nefazadone, nelfinavir, atazanavir, etc.
    boolean
    C1707479 (UMLS CUI 2011AA)
    C1142644 (UMLS CUI 2011AA)
    422741004 (SNOMED CT 2011_0131)
    C0243077 (UMLS CUI 2011AA)
    C0022625 (UMLS CUI 2011AA)
    387216007 (SNOMED CT 2011_0131)
    MTHU002299 (LOINC Version 232)
    C0064113 (UMLS CUI 2011AA)
    387532006 (SNOMED CT 2011_0131)
    MTHU002298 (LOINC Version 232)
    C0292818 (UMLS CUI 2011AA)
    386896009 (SNOMED CT 2011_0131)
    MTHU013855 (LOINC Version 232)
    C0286738 (UMLS CUI 2011AA)
    108700005 (SNOMED CT 2011_0131)
    MTHU008513 (LOINC Version 232)
    C1452484 (UMLS CUI 2011AA)
    395260006 (SNOMED CT 2011_0131)
    MTHU016681 (LOINC Version 232)
    C0068485 (UMLS CUI 2011AA)
    108435006 (SNOMED CT 2011_0131)
    MTHU003461 (LOINC Version 232)
    C0525005 (UMLS CUI 2011AA)
    108706004 (SNOMED CT 2011_0131)
    MTHU013848 (LOINC Version 232)
    C1145759 (UMLS CUI 2011AA)
    413591007 (SNOMED CT 2011_0131)
    MTHU018644 (LOINC Version 232)
    Moderate and severe hepatic impairment
    Item
    Moderate and severe hepatic impairment
    boolean
    C1881878 (UMLS CUI 2011AA)
    C0205082 (UMLS CUI 2011AA)
    24484000 (SNOMED CT 2011_0131)
    C0948807 (UMLS CUI 2011AA)
    10052254 (MedDRA 14.1)

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial